Evidence map›Paper›PMID 37190290›Full record

ReviewCancers2023

Spatially Guided and Single Cell Tools to Map the Microenvironment in Cutaneous T-Cell Lymphoma.

Eirini Kalliara, Emma Belfrage, Urban Gullberg, Kristina Drott, Sara Ek

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. What Is New in Cutaneous T Cell Lymphoma?Current oncology reports · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Eirini KalliaraDepartment of Immunotechnology, Faculty of Engineering (LTH), University of Lund, 223 63 Lund, Sweden.ORCID 0000-0001-8772-0729
Emma BelfrageDepartment of Dermatology and Venereology, Skane University Hospital (SUS), 205 02 Lund, Sweden.ORCID 0000-0003-1717-0842
Urban GullbergDepartment of Hematology and Transfusion Medicine, Skane University Hospital (SUS), 205 02 Lund, Sweden.
Kristina DrottDepartment of Hematology and Transfusion Medicine, Skane University Hospital (SUS), 205 02 Lund, Sweden.
Sara EkDepartment of Immunotechnology, Faculty of Engineering (LTH), University of Lund, 223 63 Lund, Sweden.ORCID 0000-0002-1388-4912
Skåne University Hospital · SELund University · SE

Funding

Berta Kamprad foundation FBKS-2019-14 - (210)European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 847583Swedish Cancer Society S19 0238 Pj
6 · The paper itself

Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) are two closely related clinical variants of cutaneous T-cell lymphomas (CTCL). Previously demonstrated large patient-to-patient and intra-patient disease heterogeneity underpins the importance of personalized medicine in CTCL. Advanced stages of CTCL are characterized by dismal prognosis, and the early identification of patients who will progress remains a clinical unmet need. While the exact molecular events underlying disease progression are poorly resolved, the tumor microenvironment (TME) has emerged as an important driver. In particular, the Th1-to-Th2 shift in the immune response is now commonly identified across advanced-stage CTCL patients. Herein, we summarize the role of the TME in CTCL evolution and the latest studies in deciphering inter- and intra-patient heterogeneity. We introduce spatially resolved omics as a promising technology to advance immune-oncology efforts in CTCL. We propose the combined implementation of spatially guided and single-cell omics technologies in paired skin and blood samples. Such an approach will mediate in-depth profiling of phenotypic and molecular changes in reactive immune subpopulations and malignant T cells preceding the Th1-to-Th2 shift and reveal mechanisms underlying disease progression from skin-limited to systemic disease that collectively will lead to the discovery of novel biomarkers to improve patient prognostication and the design of personalized treatment strategies.

Indexed as

biomarker discoverycutaneous T-cell lymphomamycosis fungoidespatient prognosticationpersonalized medicinespatially resolved transcriptomics

Identifiers

PMID37190290
PMCPMC10136460
OpenAlexW4366424892

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.